Berocca Twist 'n' Go Original Australia - English - Department of Health (Therapeutic Goods Administration)

berocca twist 'n' go original

bayer australia ltd - ascorbic acid,biotin,calcium carbonate,calcium pantothenate,cyanocobalamin,folic acid,magnesium carbonate hydrate,magnesium sulfate dihydrate,monophosphothiamine dihydrate,nicotinamide,pyridoxine hydrochloride,riboflavine sodium phosphate,zinc citrate trihydrate -

Berocca Performance Raspberry Blackcurrant Australia - English - Department of Health (Therapeutic Goods Administration)

berocca performance raspberry blackcurrant

bayer australia ltd - ascorbic acid,biotin,calcium carbonate,calcium pantothenate,cyanocobalamin,folic acid,magnesium carbonate hydrate,magnesium sulfate dihydrate,monophosphothiamine dihydrate,nicotinamide,pyridoxine hydrochloride,riboflavin sodium phosphate,zinc citrate trihydrate -

Berocca Performance Orange effervescent tablets Australia - English - Department of Health (Therapeutic Goods Administration)

berocca performance orange effervescent tablets

bayer australia ltd - ascorbic acid,biotin,calcium carbonate,calcium pantothenate,cyanocobalamin,folic acid,magnesium carbonate hydrate,magnesium sulfate dihydrate,monophosphothiamine dihydrate,nicotinamide,pyridoxine hydrochloride,riboflavine sodium phosphate,zinc citrate trihydrate -

Magnesium Sulfate 50 % w/v Solution for Injection/Concentrate for solution for infusion Ireland - English - HPRA (Health Products Regulatory Authority)

magnesium sulfate 50 % w/v solution for injection/concentrate for solution for infusion

aurum pharmaceutical limited - magnesium sulphate heptahydrate - solution for injection and concentrate for infusion - 50 percent weight/volume - electrolyte solutions; magnesium sulfate

Magnesium Sulfate 50 % w/v Solution for Injection/Concentrate for solution for infusion Ireland - English - HPRA (Health Products Regulatory Authority)

magnesium sulfate 50 % w/v solution for injection/concentrate for solution for infusion

ethypharm - magnesium sulphate heptahydrate - solution for injection/infusion - 50 percent weight/volume - electrolyte solutions; magnesium sulfate

Physioneal 40 Glucose 3.86%w/v /38.6mg/ml Clear-Flex Solution for peritoneal dialysis Malta - English - Medicines Authority

physioneal 40 glucose 3.86%w/v /38.6mg/ml clear-flex solution for peritoneal dialysis

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - sodium hydrogen, carbonate, sodium lactate, calcium chloride, glucose monohydrate, magnesium chloride, hexahydrate, sodium chloride - solution for peritoneal dialysis - sodium hydrogen carbonate 2.1 g/l sodium lactate 1.68 g/l calcium chloride 0.184 g/l glucose monohydrate 42.5 g/l magnesium chloride hexahydrate 0.051 g/l sodium chloride 5.38 g/l - blood substitutes and perfusion solutions

MAGNESIUM SULFATE IN DEXTROSE- magnesium sulfate heptahydrate injection, solution United States - English - NLM (National Library of Medicine)

magnesium sulfate in dextrose- magnesium sulfate heptahydrate injection, solution

b. braun medical inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate in 5% dextrose injection is indicated for: - prevention of eclampsia in patients with preeclampsia - treatment of seizures and prevention of recurrent seizures in patients with eclampsia magnesium sulfate in 5% dextrose injection is contraindicated in patients: - with heart block or myocardial damage - in diabetic coma - with myasthenia gravis [see warnings and precautions (5.6)] risk summary magnesium sulfate in 5% dextrose injection is indicated in pregnant women for the prevention of eclampsia in women with preeclampsia and the treatment of seizures and prevention of recurrent seizures in women with eclampsia. fetal, neonatal, and maternal risks are discussed throughout the labeling. clinical considerations labor or delivery: magnesium sulfate in 5% dextrose injection is not approved for the treatment of pre-term labor. administration of magnesium sulfate in 5% dextrose injection to pregnant women longer than 5 to 7 days may lead to hypocalcemia and bone abnormalities in the developing fe

MAGNESIUM SULFATE KALCEKS 50 % Israel - English - Ministry of Health

magnesium sulfate kalceks 50 %

a.l. medi-market ltd. - magnesium sulfate heptahydrate - solution for injection / concentrate for solution for inj/inf - magnesium sulfate heptahydrate 500 mg / 1 ml - magnesium sulfate - magnesium sulfate kalceks 50% solution for injection or infusion is indicated for: the treatment of magnesium deficiency in hypomagnesaemiathe prevention and treatment of hypomagnesaemia in patients receiving total parenteral nutritionthe control and prevention of seizures in severe pre-eclampsiathe control and prevention of recurrent seizures in eclampsia